Tatva Chintan Skyrockets 20% on Strong Q1 Results

July 20, 2026July 20, 2026

Shares of Tatva Chintan Pharma Chem Limited surged 20% on Monday, hitting a fresh 52-week high of Rs 1,713.70 after a sharp Q1 profit jump.

For the quarter ended 30 June, the specialty chemicals maker’s revenue rose 43% year-on-year to Rs 167.1 crore. Net profit more than doubled, jumping 140% to nearly Rs 16 crore from Rs 6.65 crore in the same quarter last year.

Operating profit told a similar story. EBITDA climbed 86% to Rs 32.3 crore, and the margin expanded to 19.5% from 14.7% a year earlier.

This was the company’s best quarterly EBITDA in at least five quarters, building on steady gains through the year. Sequentially too, the numbers held up well.

Profit had stood at Rs 10.32 crore in the March quarter, so the latest print marks a solid quarter-on-quarter jump as well.

The board also used this update to approve a Rs 200 crore expansion at its upcoming Dahej-III plant in Gujarat, adding 344 kilolitres of reactor capacity over the next 21 months.

Alongside this, it raised the company’s borrowing limit to Rs 1,000 crore from Rs 300 crore and reappointed Chintan Nitinkumar Shah as managing director for another three years.

Product-wise, pharma and agrochemical intermediates made up the largest chunk of revenue this quarter at 35%, followed closely by structure directing agents at 34% and phase transfer catalysts at 26%.

Electrolyte salts and solutions accounted for the rest. Two other directors, Ajaykumar Patel and Shekhar Somani, were also reappointed as whole-time directors for the same three-year term.

At 12:19 pm, Tatva Chintan was trading at Rs 1,694.00 on the NSE, up 18.62% for the day. It’s now up nearly 70% over the past year, comfortably inside the top gainers list on the exchange today.

The future of investing is here! Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!